PMID- 17096015
OWN - NLM
STAT- MEDLINE
DCOM- 20070209
LR  - 20151119
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 21
IP  - 1
DP  - 2007 Jan
TI  - Bortezomib in relapsed multiple myeloma: response rates and duration of response 
      are independent of a chromosome 13q-deletion.
PG  - 164-8
AB  - Studies of bortezomib in patients with relapsed multiple myeloma (MM) suggested 
      that bortezomib may be active even in the presence of adverse prognostic factors. 
      We therefore evaluated 62 patients with relapsed/refractory MM who were treated 
      with single-agent bortezomib, and addressed the question whether or not the 
      negative prognostic impact of unfavorable cytogenetic abnormalities may be 
      overcome by bortezomib. By interphase fluorescence in situ hybridization (FISH), 
      a deletion of chromosome 13q14 [del(13q14)] was present in 33 patients (53%). 
      Overall response rates to bortezomib were similar in patients with and without 
      del(13q14) (45 versus 55%; P=0.66), and rates of complete remission (CR) near CR 
      were also not different between the two patient populations (18 versus 14%). 
      Three patients had a t(4;14)(p16;q32) in addition to del(13q14), and all of them 
      had a >50% paraprotein reduction. Median duration of response was 12.3 months in 
      patients with del(13q14) compared with 9.3 months in patients with normal 
      13q-status (P=0.25), and survival was also not different between the two patient 
      populations. Patients not benefiting from single-agent bortezomib were 
      characterized by the combined presence of a del(13q14) and low serum albumin 
      (median survival 4.6 months). Our results provide evidence for remarkable 
      activity of bortezomib in MM with del(13q14). Patients who do not respond to 
      bortezomib and consecutively have short time to treatment failure and overall 
      survival can be identified by low serum albumin in addition to del(13q14) and 
      should be considered for bortezomib combinations.
FAU - Sagaster, V
AU  - Sagaster V
AD  - Department of Internal Medicine I, Clinical Division of Oncology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Ludwig, H
AU  - Ludwig H
FAU - Kaufmann, H
AU  - Kaufmann H
FAU - Odelga, V
AU  - Odelga V
FAU - Zojer, N
AU  - Zojer N
FAU - Ackermann, J
AU  - Ackermann J
FAU - Kuenburg, E
AU  - Kuenburg E
FAU - Wieser, R
AU  - Wieser R
FAU - Zielinski, C
AU  - Zielinski C
FAU - Drach, J
AU  - Drach J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061109
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Boronic Acids)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Boronic Acids/*therapeutic use
MH  - Bortezomib
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 13
MH  - Cohort Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy/genetics/mortality/pathology
MH  - Prognosis
MH  - Pyrazines/*therapeutic use
MH  - Recurrence
MH  - Survival Analysis
EDAT- 2006/11/11 09:00
MHDA- 2007/02/10 09:00
CRDT- 2006/11/11 09:00
PHST- 2006/11/11 09:00 [pubmed]
PHST- 2007/02/10 09:00 [medline]
PHST- 2006/11/11 09:00 [entrez]
AID - 2404459 [pii]
AID - 10.1038/sj.leu.2404459 [doi]
PST - ppublish
SO  - Leukemia. 2007 Jan;21(1):164-8. doi: 10.1038/sj.leu.2404459. Epub 2006 Nov 9.